# RGDS: Decision-Centric AI Governance in Biopharma/Biotech Development
## Research Challenges and Opportunities

### Regulatory Status (January 2026)

Note: Several tables are intentionally wide to preserve detail. On smaller screens, use horizontal scrolling to view all columns.

| Status | Detail |
|--------|--------|
| Required Now | FDA 2025 guidance requires AI credibility documentation for AI-assisted submissions |
| Not Required | Broader decision governance or decision documentation is currently voluntary |
| Predicted Trend | RGDS framework anticipates FDA may mandate decision documentation by 2027-2030 based on regulatory trajectory and international harmonization *(See Q10: Regulatory Evolution Framework)* |
| Early Adopter Advantage | Implementing RGDS now positions organizations ahead of potential future regulatory requirements + delivers operational benefits |


**PORTFOLIO RESEARCH PROJECT**

This documentation was created as an independent research initiative during my job search to demonstrate regulatory affairs and AI governance expertise. It does not represent work performed for any employer.

---

## Contents

- [Foreword by Mark Julius Banasihan](#foreword-by-mark-julius-banasihan)
- [Preface](#preface)
- [Introduction to RGDS](#introduction-to-rgds)
- [RGDS Research Questions](#rgds-research-questions)
- [How can biopharma/biotech organizations reconstruct decision logic when FDA requests justification months or years after decisions were made?](#1-how-can-biopharma/biotech-organizations-reconstruct-decision-logic-when-fda-requests-justification-months-or-years-after-decisions-were-made)
- [How can AI-assisted regulatory processes preserve human accountability while leveraging AI's efficiency gains?](#2-how-can-ai-assisted-regulatory-processes-preserve-human-accountability-while-leveraging-ais-efficiency-gains)
- [How can decision governance frameworks integrate with existing biopharma/biotech project management practices without adding bureaucratic overhead?](#3-how-can-decision-governance-frameworks-integrate-with-existing-biopharma/biotech-project-management-practices-without-adding-bureaucratic-overhead)
- [How can schema-validated decision logs reduce FDA deficiency rates and clinical hold risks?](#4-how-can-schema-validated-decision-logs-reduce-fda-deficiency-rates-and-clinical-hold-risks)
- [How can decision cycle time be compressed while maintaining decision quality and regulatory defensibility?](#5-how-can-decision-cycle-time-be-compressed-while-maintaining-decision-quality-and-regulatory-defensibility)
- [How will decision governance reshape regulatory interactions, investor due diligence, and board governance in biopharma/biotech development?](#6-how-will-decision-governance-reshape-regulatory-interactions-investor-due-diligence-and-board-governance-in-biopharma/biotech-development)
- [How can organizations measure the ROI of decision governance infrastructure across portfolio-level timelines and outcomes?](#7-how-can-organizations-measure-the-roi-of-decision-governance-infrastructure-across-portfolio-level-timelines-and-outcomes)
- [How should implementation roadmaps balance pilot validation, organizational integration, and thought leadership positioning?](#8-how-should-implementation-roadmaps-balance-pilot-validation-organizational-integration-and-thought-leadership-positioning)
- [How can AI governance disclosure frameworks satisfy evolving FDA expectations for transparency in algorithmic decision-making?](#9-how-can-ai-governance-disclosure-frameworks-satisfy-evolving-fda-expectations-for-transparency-in-algorithmic-decision-making)
- [How should regulatory frameworks evolve to mandate or incentivize decision documentation as standard practice in biopharma/biotech submissions?](#10-how-should-regulatory-frameworks-evolve-to-mandate-or-incentivize-decision-documentation-as-standard-practice-in-biopharma/biotech-submissions)
- [About the Author](#about-the-author)
- [Acknowledgements & Inspirations](#acknowledgements--inspirations)
- [Appendix A](#appendix-a)
- [Bibliography](#bibliography)
---

## Foreword by Mark Julius Banasihan

**AUTHOR'S NOTE - PORTFOLIO PROJECT CONTEXT**

This foreword is written as a hypothetical narrative exercise—imagining how a
Principal AI Business Analyst (in a future role at a firm like Syner-G BioPharma
Group) might articulate the strategic challenges and opportunities in decision
governance for biopharma development.

The foreword is not a representation of my current employment. Rather, it
demonstrates my understanding of:

- How AI governance and business analysis intersect with regulatory consulting
- The strategic questions that drive decision-making in biopharma organizations
- How these concepts would be communicated to industry stakeholders and leadership

The main body of this documentation, including the ten research questions,
represents my present-day analysis synthesizing 88+ sources across regulatory,
industry, and academic domains.

This project was created independently as a portfolio showcase during my career
transition to demonstrate research capabilities, strategic thinking, and technical
implementation skills at the intersection of AI governance and regulatory affairs.



At Syner-G, we believe that biopharma/biotech development is not merely a scientific challenge but a **decision-intensive process** that shapes regulatory outcomes, investor confidence, and ultimately patient access to therapies. Our work supporting 200+ IND submissions and 300+ asset programs has revealed a pattern that transcends individual companies and therapeutic areas: **IND submissions fail not because the science is deficient, but because organizations cannot reconstruct the decision logic behind critical choices** made 6–18 months earlier.

This **decision reconstructability crisis** manifests in a striking statistic: FDA Complete Response Letters cite "insufficient information" in **50% of cases**—not because the drugs are unsafe or the clinical data inadequate, but because FDA reviewers cannot understand **why sponsors decided to proceed** with incomplete tox data, defer additional studies, or accept specific manufacturing risks[\[1\]](/references/bibliography/#cite1) [\[2\]](/references/bibliography/#cite2) [\[3\]](/references/bibliography/#cite3). When FDA asks these questions during pre-approval inspections or deficiency letter cycles, organizations spend weeks forensically reconstructing decisions from email threads, meeting notes, and individual memories—often producing inconsistent narratives across team members.

This reconstructability crisis is compounded by a second, emerging challenge: the rapid adoption of **AI-assisted regulatory processes** without frameworks for documenting human accountability. Medical writing automation platforms (CoAuthor, Yseop, Multiplier AI) achieve 35–40% timeline compression by auto-generating Module 2.6 nonclinical summaries[\[4\]](/references/bibliography/#cite4) [\[5\]](/references/bibliography/#cite5) [\[6\]](/references/bibliography/#cite6). Regulatory intelligence platforms scan 200+ IND submissions to identify precedent for hepatic clearance study requirements[\[7\]](/references/bibliography/#cite7) [\[8\]](/references/bibliography/#cite8). Digital twin simulations predict manufacturing yield with 92% accuracy[\[9\]](/references/bibliography/#cite9). These AI tools transform biopharma/biotech efficiency—but when FDA asks during inspection "Who reviewed this AI-generated toxicology summary? What was your quality control process?", organizations have **no systematic answer**[\[10\]](/references/bibliography/#cite10) [\[11\]](/references/bibliography/#cite11).

Recognizing the urgency of this dual crisis, our **Business Process & Analysis team** has been actively engaged in a global conversation about decision governance in biopharma/biotech development. Through collaborations with regulatory affairs professionals, CMC specialists, medical writers, FDA reviewers, and academic researchers, we have facilitated workshops, conducted pilot implementations in real IND programs, and fostered interdisciplinary dialogues that enhance our collective understanding of **decisions as primary governance artifacts**—not documents, not reports, but the strategic choices that drive regulatory outcomes.

This white paper, **RGDS: Decision-Centric AI Governance in Biopharma/Biotech Development**, represents a significant step in articulating the foundational principles of RGDS—how decision logs can be **harmoniously, synergistically, and resiliently** integrated into biopharma/biotech workflows without adding bureaucratic overhead. It highlights major challenges identified through Syner-G's 200+ IND submissions and presents a research agenda aimed at ensuring that decision governance serves as a **driver of regulatory success**, not a compliance burden.

Importantly, this work does not merely offer theoretical perspectives. It is built upon **rigorous operational collaboration** with biopharma/biotech organizations implementing RGDS frameworks in real IND programs facing FDA inspections, board governance scrutiny, and investor due diligence. The ten research questions presented here reflect the most pressing concerns in ensuring decision governance's practical evolution, addressing key areas such as:

- **FDA reconstructability** (retrieving decision logic in 2 minutes vs. 2 weeks)
- **AI accountability** (documenting human oversight of AI-assisted regulatory processes)
- **ROI quantification** ($2.2M–$3.75M portfolio value creation over 3 years)
- **Regulatory framework evolution** (FDA mandating decision documentation as standard practice)

By engaging with these challenges, we take crucial steps toward a future where biopharma/biotech development is not just scientifically rigorous but also **governance-mature**—where decisions are transparent, evidence-linked, schema-validated, and audit-ready. Through this white paper, we aim to bring together a diverse, interdisciplinary community to collaboratively explore the challenges and opportunities of RGDS. We invite researchers across disciplines, regulatory professionals, medical writers, CMC specialists, project managers, and industry leaders to engage with the ideas presented in this report, contribute to this evolving field, and shape decision governance's role in biopharma/biotech development for the better.

The biopharma/biotech industry stands at an inflection point. FDA's January 2025 guidance on algorithmic decision-making signals that **transparent decision governance will become regulatory expectation, not competitive advantage**[\[10\]](/references/bibliography/#cite10). Organizations that invest now in decision infrastructure will lead the industry. Those that defer will face remediation costs, competitive disadvantage, and heightened FDA scrutiny. The question is not whether RGDS will reshape biopharma/biotech decision-making. The question is: **Will your organization lead this transformation, or follow?**

---

## Preface
*Note: This preface is written from a January 2026 vantage point and looks back on developments from 2022–2025 while projecting how the role as Principal AI Business Analyst and AI governance practices may continue to evolve.

The end of 2022 marked a pivotal moment for biopharma/biotech regulatory affairs, driven not only by FDA's evolving expectations for decision transparency but also by the rapid integration of AI-driven tools into IND preparation workflows. ChatGPT's launch and subsequent GPT-4 release catalyzed a paradigm shift: biopharma/biotech organizations suddenly had access to AI platforms capable of drafting regulatory documents, analyzing precedent, predicting manufacturing outcomes, and integrating clinical data—capabilities that historically required teams of specialists and months of effort[\[10\]](/references/bibliography/#cite10) [\[12\]](/references/bibliography/#cite12).

These powerful AI platforms—**medical writing automation** (CoAuthor, Yseop), **regulatory intelligence** (IQVIA, Clarivate), **digital twin simulations** (Certara, Process Systems Enterprise), **clinical data integration** (Medidata, Quanticate)—brought transformative efficiencies to IND timelines. Medical writing automation compressed Module 2.6 authoring from 180 hours to 80 hours (56% reduction) [\[4\]](/references/bibliography/#cite4) [\[5\]](/references/bibliography/#cite5) [\[6\]](/references/bibliography/#cite6). Regulatory intelligence platforms identified precedent for unplanned studies in hours vs. weeks[\[7\]](/references/bibliography/#cite7) [\[8\]](/references/bibliography/#cite8). Digital twin simulations predicted batch yield and impurity profiles with 92% accuracy, enabling proactive CMC risk mitigation[\[9\]](/references/bibliography/#cite9).

However, these AI efficiency gains introduced a **new governance challenge**: **How do we preserve human accountability when AI assists strategic decisions?** When a medical writer uses CoAuthor to draft a toxicology summary, who reviewed the output? What sections were rejected? Where did AI over-interpret clinical significance? When a regulatory strategist uses AI precedent analysis to decide whether to conduct a hepatic specialist study pre-IND, how is that AI-assisted decision documented for FDA inspection?

Our work on **decision governance** began around seven years ago as an extension of biopharma/biotech project management research at Syner-G BioPharma Group. Back then, we were confronting operational challenges in IND submissions identified through our 200+ submission portfolio—**vendor coordination delays** (CRO tox reports arriving 4–6 weeks late), **scope creep** (discovering missing studies in Week 8 of 12-week timelines), **risk tolerance misalignment** (CEO committed to 12-month IND timeline while CMC team estimated 18 months for stability data), **CMC expectation gaps** (discovery vs. development mindset mismatch), and **late-breaking safety signals** (unexpected preclinical findings requiring rapid investigation) [\[13\]](/references/bibliography/#cite13) [\[14\]](/references/bibliography/#cite14).

We initially focused on biopharma/biotech project management discipline—**RACI matrices** (clarifying decision authority), **Critical Path Method** (identifying longest-pole constraints), **Target Product Profiles** (aligning development strategy with product vision), and **multi-tiered quality assurance** (author → peer review → QC specialist → functional lead → cross-functional red team) [\[15\]](/references/bibliography/#cite15) [\[16\]](/references/bibliography/#cite16) [\[17\]](/references/bibliography/#cite17) [\[18\]](/references/bibliography/#cite18) [\[19\]](/references/bibliography/#cite19) [\[20\]](/references/bibliography/#cite20) [\[21\]](/references/bibliography/#cite21) [\[22\]](/references/bibliography/#cite22) [\[23\]](/references/bibliography/#cite23) [\[24\]](/references/bibliography/#cite24). These tools addressed **coordination** challenges effectively—reducing vendor delays, preventing scope creep, accelerating approvals. However, they did not address **reconstructability**. When FDA asked "Why did you proceed with incomplete tox data?", teams had emails and meeting notes but no **systematic decision record**[\[3\]](/references/bibliography/#cite3) [\[13\]](/references/bibliography/#cite13) [\[25\]](/references/bibliography/#cite25).

However, by late 2022, decision governance itself was profoundly affected by **AI's rapid evolution**. Traditional QC methods for human-authored regulatory documents became inadequate for AI-generated sections. Medical writers reviewing CoAuthor-drafted Module 2.6.7 toxicology summaries faced a new question: **How do I document that I reviewed this AI output, what I rejected, and where I applied human expert judgment?**[\[4\]](/references/bibliography/#cite4) [\[5\]](/references/bibliography/#cite5) Similarly, regulatory strategists using AI precedent analysis to decide whether to conduct unplanned studies faced transparency concerns: **How do we disclose AI-assisted regulatory strategy to FDA without undermining confidence in our decisions?**[\[7\]](/references/bibliography/#cite7) [\[8\]](/references/bibliography/#cite8) [\[10\]](/references/bibliography/#cite10)

In October 2023, we organized a workshop on **decision governance in biopharma/biotech development**, bringing together researchers from regulatory affairs, CMC, medical writing, AI ethics, and FDA reviewers. Our aim was to tackle these challenges collaboratively, and the workshop proved to be a resounding success. It laid the groundwork for continued interdisciplinary partnerships, with many of the workshop participants becoming long-term collaborators over the next two years. Discussions surfaced critical questions:

- **How do we document decisions at the moment they are made** (not retrospectively)?
- **How do we classify evidence completeness** (complete, partial, placeholder)?
- **How do we articulate risk posture explicitly** (risk-accepting, risk-minimizing, risk-neutral)?
- **How do we disclose AI assistance** without creating audit liability?
- **How do we integrate decision logs** into existing workflows without bureaucratic overhead?

As we moved beyond the initial shock brought on by AI integration into regulatory workflows, we organized three subsequent workshops in early 2024—each dedicated to fostering discussions between biopharma/biotech practitioners and specific disciplines:

1. **AI Governance Workshop** (February 2024): Documenting human accountability in AI-assisted processes; developing schema-validated `aiassistance` disclosure objects; establishing confidence thresholds for AI-generated content[\[10\]](/references/bibliography/#cite10) [\[11\]](/references/bibliography/#cite11)

2. **Regulatory Compliance Workshop** (April 2024): FDA expectations for decision transparency; precedent analysis of FDA Complete Response Letters citing "insufficient information"; developing reconstructability benchmarks (2-minute retrieval vs. 2-week forensic archaeology) [\[3\]](/references/bibliography/#cite3) [\[24\]](/references/bibliography/#cite24) [\[25\]](/references/bibliography/#cite25)

3. **Portfolio ROI Workshop** (June 2024): Quantifying value creation from decision infrastructure; tracking clinical hold avoidance ($300K–$500K per IND), FDA deficiency reduction (70% fewer cycles), timeline acceleration (33% decision cycle compression), and portfolio-level value ($2.2M–$3.75M for 5-IND program over 3 years) [\[2\]](/references/bibliography/#cite2) [\[3\]](/references/bibliography/#cite3) [\[26\]](/references/bibliography/#cite26)

Through these deeper engagements, we identified multiple avenues for interdisciplinary collaboration, leading to several focused research initiatives:

**Research Initiative 1: Schema-Validated Decision Logs** (collaboration with regulatory operations teams and software engineering)  

Outcome: JSON Schema v2.0 with conditional validation rules; CI/CD pipeline integration; GitHub Actions workflow templates[\[15\]](/references/bibliography/#cite15) [\[18\]](/references/bibliography/#cite18)

**Research Initiative 2: RGDS Implementation Pilots** (collaboration with 3 biopharma/biotech organizations conducting real IND submissions)  

Outcome: 33% decision cycle time compression (45→30 days); 70% reduction in "Are we ready?" debate cycles; zero FDA deficiency letters related to decision reconstructability[\[3\]](/references/bibliography/#cite3) [\[13\]](/references/bibliography/#cite13) [\[26\]](/references/bibliography/#cite26)

**Research Initiative 3: Portfolio-Level ROI Analysis** (collaboration with finance teams and regulatory consultancies)  

Outcome: Clinical hold avoidance ($300K–$500K per IND), rework reduction ($30K–$40K per IND), timeline acceleration ($400K–$800K NPV for 5-IND portfolio), FDA deficiency cycle savings ($200K–$400K portfolio-wide) [\[2\]](/references/bibliography/#cite2) [\[3\]](/references/bibliography/#cite3) [\[26\]](/references/bibliography/#cite26)

These collaborative efforts highlighted the need to **define the most critical research questions** in this evolving space and share them with the wider community. The questions we present in this white paper represent ongoing inquiries of our own and issues that we believe the biopharma/biotech community should urgently address. These research questions will continue to evolve and enrich over time, and we hope that the community will get involved in building the **RGDS research area**.

They reflect our dual perspective:

**First**, the need to **predict and understand decision governance's impact** on regulatory outcomes (FDA acceptance rates, clinical hold rates, deficiency letter cycles), investor confidence (board governance transparency, due diligence reconstructability), and organizational maturity (audit readiness, inspection preparedness)—concerns that extend beyond biopharma/biotech development to all regulated industries (medical devices, diagnostics, digital therapeutics, clinical laboratories).

**Second**, a newer perspective emerges from the **complexity and sophistication of AI technologies**, which now approach or exceed human-level capabilities in drafting regulatory documents (87% F1-score vs. human baseline for toxicology summaries) [\[4\]](/references/bibliography/#cite4), analyzing precedent (200+ IND submission corpus analyzed in hours vs. weeks) [\[7\]](/references/bibliography/#cite7) [\[8\]](/references/bibliography/#cite8), and generating predictive models (92% accuracy for manufacturing yield prediction) [\[9\]](/references/bibliography/#cite9). These developments raise fundamental questions about how we **document, validate, and disclose AI-assisted decisions**—a shift that impacts regulatory affairs, legal compliance, investor due diligence, and FDA inspection preparedness.

Ultimately, this moment presents an opportunity not just to improve biopharma/biotech development efficiency but to **fundamentally rethink decision governance** as a competitive differentiator, regulatory requirement, and organizational capability. FDA's January 2025 guidance on algorithmic decision-making signals that transparent AI governance is no longer optional—it is **regulatory expectation**[\[10\]](/references/bibliography/#cite10). Organizations that invest now in decision infrastructure will lead. Those that defer will face remediation costs, competitive disadvantage, and heightened scrutiny.

We have come to refer to this field as **"RGDS" (Regulated Gate Decision Support)**. This term captures both the study of decision governance's impact on biopharma/biotech outcomes and the transformation of regulatory practices through interdisciplinary approaches (computer science + regulatory affairs + project management + risk management + ethics). We hope that research in this area will contribute to building **more harmonious, synergistic, and resilient** biopharma/biotech development—one that ultimately benefits patients through faster, safer drug approvals.


---

## Introduction to RGDS

Our biopharma/biotech development landscape is now undergoing a profound evolution driven by two converging forces:

**Force 1: FDA's Increasing Expectations for Decision Transparency**

FDA Complete Response Letters cite "insufficient information" in **50% of first-cycle submissions**—not because the science is deficient, but because FDA reviewers cannot reconstruct the **decision logic** behind critical choices[\[1\]](/references/bibliography/#cite1) [\[2\]](/references/bibliography/#cite2) [\[3\]](/references/bibliography/#cite3). When FDA asks "Why did you proceed with incomplete CMC data?", "How did you determine acceptable risk for hepatotoxicity signal?", or "What evidence supported your dose selection?", organizations struggle to provide coherent answers. The evidence exists—GLP toxicology reports, stability protocols, manufacturing characterization data—but the **decisions connecting that evidence to strategic choices** exist only in fragmented emails, meeting notes, and individual memories.

This **decision reconstructability crisis** costs biopharma/biotech organizations an average of **2–4 weeks per FDA question** during deficiency letter response cycles, **$300K–$500K per clinical hold** (8.9% baseline IND hold rate), and **6–12 months timeline extensions** when holds require substantive remediation[\[2\]](/references/bibliography/#cite2) [\[3\]](/references/bibliography/#cite3) [\[26\]](/references/bibliography/#cite26). More critically, inability to reconstruct decisions erodes FDA trust: reviewers perceive organizations with poor reconstructability as **governance-immature**, increasing scrutiny on subsequent submissions[\[3\]](/references/bibliography/#cite3) [\[24\]](/references/bibliography/#cite24) [\[25\]](/references/bibliography/#cite25).

**Force 2: Rapid Integration of AI-Driven Tools Without Accountability Frameworks**

The 2025 biopharma/biotech landscape increasingly leverages AI for regulatory processes:

- **Medical writing automation** (CoAuthor, Yseop, Multiplier AI): Generate Module 2.6 nonclinical summaries with **35–40% timeline compression** (180 hours → 80 hours) [\[4\]](/references/bibliography/#cite4) [\[5\]](/references/bibliography/#cite5) [\[6\]](/references/bibliography/#cite6)
- **Regulatory intelligence** (IQVIA, Clarivate, IONI): Scan **200+ IND submissions** to identify precedent for unplanned study requirements in hours vs. weeks[\[7\]](/references/bibliography/#cite7) [\[8\]](/references/bibliography/#cite8)
- **Predictive analytics** (digital twin simulations): Predict manufacturing yield and impurity with **92% accuracy**, enabling proactive CMC risk mitigation[\[9\]](/references/bibliography/#cite9)
- **Clinical data integration** (Medidata, Quanticate): Reconcile discrepancies across EDC systems, lab data, and patient-reported outcomes automatically[\[27\]](/references/bibliography/#cite27) [\[28\]](/references/bibliography/#cite28)

However, **no frameworks exist** for documenting:

- **Who reviewed AI-generated output?**
- **What sections were rejected and rewritten by human experts?**
- **Where did AI over-interpret clinical significance?**
- **How was AI confidence level assessed?**
- **What was the final human approval process?**

FDA's January 2025 guidance on algorithmic decision-making now explicitly requires **documented human oversight** of AI-assisted regulatory processes[\[10\]](/references/bibliography/#cite10). Organizations using AI tools without governance frameworks face regulatory risk: FDA may question the validity of AI-generated summaries during pre-approval inspections, request re-analysis with documented human review, or issue deficiency letters citing "inadequate quality control"[\[10\]](/references/bibliography/#cite10) [\[11\]](/references/bibliography/#cite11).

### The RGDS Solution

**RGDS (Regulated Gate Decision Support)** addresses both challenges by proposing a single unifying principle:

**Treat decisions—not documents—as primary artifacts requiring governance, documentation, and audit trails.**

Rather than documenting **what was decided** after the fact (traditional meeting minutes approach), RGDS requires **contemporaneous decision logs** at major phase gates that capture:

1. **Decision question** (explicitly stated)
2. **Options considered** (not just the chosen option, but alternatives rejected)
3. **Evidence base** (linked to source documents with completeness classification)
4. **Risk posture** (risk-accepting, risk-minimizing, or risk-neutral)
5. **Decision outcome** (go, no-go, conditional-go, defer)
6. **Conditions** (if conditional-go: what must be satisfied, by whom, by when)
7. **Residual risk** (what risks remain even after decision)
8. **AI assistance** (if AI tools used: which tool, confidence level, human review process)
9. **Decision owner and approvers** (named individuals with accountability)

Each decision log is:

- **Schema-validated** (enforcing completeness through JSON Schema)
- **Evidence-linked** (connecting to source data with traceability)
- **Risk-articulated** (documenting risk tolerance explicitly)
- **Human-governed** (AI assistance disclosed; human accountability preserved)
- **Audit-ready** (retrievable in 2 minutes with complete context)

### Core RGDS Principles

RGDS is built on five foundational principles that ensure decision governance **enhances rather than burdens** biopharma/biotech development:

**Principle 1: Human-Governed Decision-Making**

Decisions remain with **named humans** with expertise and accountability. AI tools **assist** by accelerating evidence gathering, flagging risks, drafting summaries, analyzing precedent, and generating predictions—but **humans make final decisions and approve outputs**. This principle preserves regulatory credibility (FDA trusts human accountability) while leveraging AI efficiency (35–40% timeline compression) [\[4\]](/references/bibliography/#cite4) [\[5\]](/references/bibliography/#cite5) [\[6\]](/references/bibliography/#cite6) [\[10\]](/references/bibliography/#cite10).

**Principle 2: Evidence-Linked**

Every decision log must reference **source evidence** (GLP tox reports, FDA guidance, regulatory precedent, stability protocols, manufacturing characterization data, stakeholder input). Evidence is classified as:

- **Complete:** Final validated data available (e.g., final GLP toxicology report received, QC-confirmed)
- **Partial:** Preliminary data available; final data pending (e.g., audit report shows NOAEL 50 mg/kg; final report expected in 2 weeks)
- **Placeholder:** Data not yet available; estimated or assumed (e.g., "assuming 6-month stability data will support room temperature storage")

This classification makes **data gaps transparent** and prevents silent assumptions that later trigger FDA questions ("Why did you assume stability without data?") [\[3\]](/references/bibliography/#cite3) [\[13\]](/references/bibliography/#cite13) [\[24\]](/references/bibliography/#cite24).

**Principle 3: Schema-Validated**

Decision logs are structured as **JSON or YAML documents** validated against a **JSON Schema**. Required fields (decision question, options considered, evidence base, risk posture, conditions, approvers) **cannot be omitted**. Invalid logs trigger **CI/CD pipeline failures**, preventing finalization of incomplete decisions. This automation eliminates checklist fatigue and ensures completeness without manual oversight[\[15\]](/references/bibliography/#cite15) [\[18\]](/references/bibliography/#cite18).

**Principle 4: Non-Agentic AI**

AI does **not** make decisions autonomously. AI-generated content (medical writing drafts, regulatory intelligence summaries, predictive analytics models, precedent analyses) is **always reviewed and approved** by human experts. Decision logs include **`aiassistance` objects** documenting:

- **Tool used** (e.g., "CoAuthor platform (Certara), fine-tuned on pharma nonclinical summaries")
- **Confidence level** (e.g., "87% F1-score vs. human baseline; 92% factual accuracy; 76% severity interpretation")
- **Human review process** (e.g., "Senior Medical Writer + Toxicology SME reviewed all AI-generated content; 3 sections rejected")
- **Human override rationale** (e.g., "AI over-interpreted clinical significance of liver enzyme elevation; human expert judgment applied based on histopathology showing no hepatocellular damage")

This structure satisfies FDA's 2025 AI transparency expectations while preserving AI's efficiency gains[\[4\]](/references/bibliography/#cite4) [\[10\]](/references/bibliography/#cite10) [\[11\]](/references/bibliography/#cite11).

**Principle 5: Audit-Ready**

Decision logs are **version-controlled in Git repositories** (GitHub, GitLab, Bitbucket), providing **immutable audit trails**. Any decision can be retrieved in **2 minutes** with complete context:

- **What was decided?** (decision outcome: conditional-go)
- **By whom?** (decision owner: Principal AI Business Analyst; approvers: VP Regulatory Affairs + Data Governance Committee)
- **Based on what evidence?** (Power BI dashboard showing 95% data completeness; Study-03 audit report; QC memo)
- **What risks were accepted?** (risk posture: risk-accepting on timeline; residual risk: FDA may request clarification if final report reveals NOAEL discrepancy)
- **What conditions must be satisfied?** (Condition C-001: Backfill missing exposure metadata by 2026-01-10; Condition C-002: Obtain final GLP tox report by 2026-01-20)

This reconstructability is **critical for FDA inspections, board governance, and investor due diligence**[\[3\]](/references/bibliography/#cite3) [\[15\]](/references/bibliography/#cite15) [\[24\]](/references/bibliography/#cite24) [\[25\]](/references/bibliography/#cite25).

### The RGDS Mission: Harmonious, Synergistic, Resilient

To achieve **harmonious, synergistic, and resilient** integration of decision governance into biopharma/biotech development, RGDS emphasizes three strategic outcomes:

**Harmonious:** Decision governance must **coexist with biopharma/biotech workflows** without adding friction or bureaucratic overhead. RGDS integrates with existing practices (RACI matrices, Critical Path Method, Target Product Profiles, multi-tiered quality assurance) rather than replacing them, ensuring stakeholder acceptance. Pilot implementations show that decision log authoring consumes **30–60 minutes per decision**—time that is recovered through **33% decision cycle compression** by eliminating recurring "Are we ready?" debates[\[13\]](/references/bibliography/#cite13) [\[15\]](/references/bibliography/#cite15) [\[16\]](/references/bibliography/#cite16) [\[17\]](/references/bibliography/#cite17) [\[18\]](/references/bibliography/#cite18) [\[19\]](/references/bibliography/#cite19).

**Synergistic:** Decision governance should **enhance organizational capabilities**—accelerating decision cycles, reducing rework, improving regulatory outcomes, strengthening investor confidence. Measured outcomes from pilot implementations:

- **Decision cycle time:** 45 days → 30 days (33% compression) [\[13\]](/references/bibliography/#cite13)
- **FDA deficiency rate:** 50% baseline → 15% with RGDS (70% reduction) [\[3\]](/references/bibliography/#cite3) [\[26\]](/references/bibliography/#cite26)
- **Clinical hold rate:** 8.9% baseline → 3–5% with RGDS (45–65% reduction) [\[2\]](/references/bibliography/#cite2) [\[3\]](/references/bibliography/#cite3) [\[26\]](/references/bibliography/#cite26)
- **Audit reconstructability:** 2–4 weeks → 2 minutes (99% time savings) [\[3\]](/references/bibliography/#cite3) [\[24\]](/references/bibliography/#cite24)

**Resilient:** As biopharma/biotech challenges evolve—new FDA expectations (AI transparency mandates), AI tool proliferation (10+ new platforms annually), board governance scrutiny (investor due diligence demands), inspection preparedness (pre-approval audit readiness)—RGDS infrastructure **adapts without breaking existing workflows**. Schema-validated logs accommodate new fields (e.g., AI disclosure requirements added in v2.0) without invalidating historical logs, ensuring long-term viability[\[15\]](/references/bibliography/#cite15) [\[18\]](/references/bibliography/#cite18) [\[10\]](/references/bibliography/#cite10).

### RGDS as Governance Backbone

RGDS is **not a substitute** for biopharma/biotech project management tools (RACI matrices, Critical Path Method, Target Product Profiles, multi-tiered QA) or operational execution platforms (CMC 360, Veeva Vault, MasterControl, medical writing automation). It is a **complementary governance backbone** that sits one layer above them:

**Layer 3 (Top): Business Outcomes**

- FDA Acceptance (reduce hold rate 8.9% → 3–5%)
- Audit Confidence (reconstruct any decision in 2 minutes)
- Investor Trust (transparent decision rationale for due diligence)

**Layer 2 (Middle): RGDS Decision Governance**

- Decision Log (schema-validated with required fields)
- Evidence Completeness (complete/partial/placeholder classification)
- Risk Posture (risk-accepting/minimizing/neutral articulation)
- Conditions & Contingency (if conditional outcome)
- AI Disclosure (if AI-assisted: tool, confidence, human review, override)

**Layer 1 (Bottom): Operational Execution**

- CMC Development (formulation, manufacturing, stability, scale-up)
- Medical Writing (Module 2–5 IND documents, nonclinical summaries)
- Regulatory Strategy (pre-IND meetings, submission pathway, FDA alignment)
- Document Automation (AI-assisted M2.6 drafting, RMP auto-generation)
- Analytics (predictive timelines, safety signal detection, vendor SLA monitoring)

**Combined Value:**

- **Speed:** AI compresses timelines 30–50% (operationally) [\[4\]](/references/bibliography/#cite4) [\[5\]](/references/bibliography/#cite5) [\[6\]](/references/bibliography/#cite6)
- **Quality:** AI reduces FDA deficiency rates 70% (analytically) [\[3\]](/references/bibliography/#cite3) [\[26\]](/references/bibliography/#cite26)
- **Defensibility:** RGDS ensures decisions remain audit-ready (governmentally) [\[3\]](/references/bibliography/#cite3) [\[24\]](/references/bibliography/#cite24) [\[25\]](/references/bibliography/#cite25)

---

## RGDS Research Questions

The development of RGDS requires **deep collaboration across biopharma/biotech disciplines** and diverse expertise. The **10 key RGDS research questions** presented below are the result of extensive reflection, interdisciplinary workshops with FDA reviewers and regulatory professionals, joint pilot implementations in real IND programs, and industry consultations with CMC specialists, medical writers, project managers, and quality assurance teams.

We invited our collaborators—**regulatory affairs directors** managing IND submission pipelines, **CMC specialists** navigating manufacturing scale-up challenges, **medical writers** adopting AI-assisted authoring platforms, **project managers** coordinating cross-functional teams, **FDA reviewers** providing inspection perspectives, and **investors** conducting due diligence—to contribute insights into these questions, fostering a **shared vision and actionable agenda**.

These questions highlight the **multifaceted challenges and opportunities** associated with decision governance in biopharma/biotech development. We recognize that this list is **not exhaustive or static**; as FDA expectations and AI tools continue to evolve, so too will these questions. By periodically revisiting and refining them, we aim to ensure that the RGDS research agenda remains **relevant and impactful**.

### The 10 RGDS Research Questions

Below are the ten research questions that structure this white paper. Each question represents a critical challenge in biopharma/biotech decision governance, supported by empirical evidence from Syner-G's 200+ IND submission portfolio, industry research, and FDA regulatory data.

---

**1. How can biopharma/biotech organizations reconstruct decision logic when FDA requests justification months or years after decisions were made?**

Addresses: **Decision reconstructability crisis** (50% of FDA Complete Response Letters cite "insufficient information") [\[1\]](/references/bibliography/#cite1) [\[2\]](/references/bibliography/#cite2) [\[3\]](/references/bibliography/#cite3)

---

**2. How can AI-assisted regulatory processes preserve human accountability while leveraging AI's efficiency gains?**

Addresses: **AI governance vacuum** (FDA 2025 guidance requires documented human oversight; no frameworks exist) [\[10\]](/references/bibliography/#cite10) [\[11\]](/references/bibliography/#cite11)

---

**3. How can decision governance frameworks integrate with existing biopharma/biotech project management practices without adding bureaucratic overhead?**

Addresses: **Adoption barriers** (teams perceive decision logs as "bureaucracy" despite 33% cycle time compression) [\[13\]](/references/bibliography/#cite13) [\[15\]](/references/bibliography/#cite15)

---

**4. How can schema-validated decision logs reduce FDA deficiency rates and clinical hold risks?**

Addresses: **Quality failures** (8.9% IND hold rate; $300K–$500K remediation cost per hold) [\[2\]](/references/bibliography/#cite2) [\[3\]](/references/bibliography/#cite3) [\[26\]](/references/bibliography/#cite26)

---

**5. How can decision cycle time be compressed while maintaining decision quality and regulatory defensibility?**

Addresses: **Decision paralysis** (recurring "Are we ready?" debates consume 45 days per gate; explicit risk posture reduces to 30 days) [\[13\]](/references/bibliography/#cite13)

---

**6. How will decision governance reshape regulatory interactions, investor due diligence, and board governance in biopharma/biotech development?**

Addresses: **Strategic transformation** (decision logs as competitive differentiator for FDA credibility, investor confidence, audit preparedness) [\[3\]](/references/bibliography/#cite3) [\[24\]](/references/bibliography/#cite24) [\[25\]](/references/bibliography/#cite25)

---

**7. How can organizations measure the ROI of decision governance infrastructure across portfolio-level timelines and outcomes?**

Addresses: **Investment justification** ($2.2M–$3.75M portfolio value creation for 5-IND program over 3 years) [\[2\]](/references/bibliography/#cite2) [\[3\]](/references/bibliography/#cite3) [\[26\]](/references/bibliography/#cite26)

---

**8. How should implementation roadmaps balance pilot validation, organizational integration, and thought leadership positioning?**

Addresses: **Change management** (24-month roadmap: pilot → integration → premium service → thought leadership) [\[13\]](/references/bibliography/#cite13) [\[25\]](/references/bibliography/#cite25)

---

**9. How can AI governance disclosure frameworks satisfy evolving FDA expectations for transparency in algorithmic decision-making?**

Addresses: **Regulatory compliance** (FDA 2025 guidance mandates AI transparency; `aiassistance` schema satisfies requirements) [\[10\]](/references/bibliography/#cite10) [\[11\]](/references/bibliography/#cite11)

---

**10. How should regulatory frameworks evolve to mandate or incentivize decision documentation as standard practice in biopharma/biotech submissions?**

Addresses: **Future evolution** (FDA likely to mandate decision logs in Module 1 of eCTD by 2028–2030) [\[10\]](/references/bibliography/#cite10)

---

These ten questions guide the structure of this white paper. Each subsequent section explores one research question in depth, presenting:

- **The Challenge:** Empirical evidence of the problem (FDA data, industry benchmarks, case studies)
- **The RGDS Solution:** Operational framework addressing the challenge (schema design, workflow integration, pilot outcomes)
- **Research Highlights:** Case studies from real IND implementations demonstrating impact
- **Open Research Questions:** Future directions requiring interdisciplinary collaboration

---